Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $14.00. The company’s shares closed last Thursday at $4.94.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 33.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Magenta Therapeutics, and Nektar Therapeutics.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Moderate Buy with an average price target of $14.00.
The company has a one-year high of $7.94 and a one-year low of $1.42. Currently, Xeris Pharmaceuticals has an average volume of 2.37M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.